Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2022 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The transcript is about Cemig's Q3 2022 earnings call. Management discusses investments, projects, etc. They mention new projects: Boa Esperanca (100 MW peak) and Jusante (87 MW) photovoltaic plants, and distributed generation more than 30 MW in nine plants. They also mention investments of BRL 2.2 billion year-to-date, more than twice the investment in 2017-2018. They talk about opening more than 14 substations vs historical average of six. This suggests larger scale of investments. But is it about the size of individual deals/contracts/projects? They are investing more, but is that because each project is bigger? They mention new projects approved, but they don't explicitly compare the size of individual projects to past ones. They say "we have new projects already enabled and all of them will strong value generation with clients associated." They talk about the investment program accelerating. However, the question is about "successive engagements of the same kind" coming in at progressively larger size. For example, are they signing larger contracts? They mention transferring trading contracts to Cemig Holding, but that's not about size escalation. They talk about reaching 9 million consumers, but that's volume. They talk about quality indicators. They mention the investment program is robust. But do they say that each new project is bigger than the last? They mention two new photovoltaic plants with specific capacities, but they don't compare to previous ones. They also mention distributed generation with 30 MW in nine plants, but that's an average. They don't say that the size of each new project is escalating. They talk about the overall investment amount being higher, but that could be due to more projects, not larger individual ones. They also mention that they are investing more than twice as much as in 2017-2018, but that's total investment, not per project. The question specifically asks about the unit size of the company's own repeatable business escalating. For example, are they signing larger power purchase agreements? They mention that they are transferring contracts, but not that the contracts are getting bigger.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.